Seattle Biotech Startup A-Alpha Bio Raises $22.4M to Advance AI Platform for Protein Interaction Analysis

Seattle biotech startup A-Alpha Bio raised $22.4 million to advance its AI-driven platform that measures protein interactions, partnering with major drug companies like Bristol Myers Squibb and Gilead Sciences to accelerate therapeutic development. Its platform combines computational tools and yeast experiments to analyze nearly 500 million protein-protein interaction measurements for drug discovery.

RRandolph Lopez DDavid Younger MMadrona AA-Alpha Bio